ResearchMoz

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

GBI Research
Published Date » 2014-03-07
No. Of Pages » 109
   
 GBI Research, the leading business intelligence provider, has released its latest research: ‘NSCLC Therapeutics in APAC Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool’, which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8...
Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 12
2.4 Co-morbidities and Complications 12
2.5 Diagnosis 13
2.5.1 Physical Examination 13
2.5.2 Sputum Cytology 13
2.5.3 Imaging Tests 13
2.5.4 Biopsy 14
2.6 Classification 15
2.6.1 Adenocarcinoma 15
2.6.2 Squamous Cell Carcinoma 15
2.6.3 Large Cell Carcinoma 15
2.7 Epidemiology 15
2.8 Prognosis and Disease Staging 16
2.8.1 Staging 16
2.9 Treatment Options 18
2.9.1 Surgery and Radiation Therapy 18
2.9.2 Pharmacological 18
2.9.3 Treatment Algorithms and Prescribing Habits 20

3 Marketed Products 23
3.1 Therapeutic Landscape 24
3.1.1 Alimta (pemetrexed disodium) – Eli Lilly and Company 24
3.1.2 Abraxane (nab-paclitaxel) – Celgene 26
3.1.3 Iressa (gefitinib) – AstraZeneca 28
3.1.4 Tarceva (erlotinib hydrochloride) – F. Hoffmann-La Roche 29
3.1.5 Xalkori (crizotinib) – Pfizer 31
3.1.6 Avastin (bevacizumab) – F. Hoffmann-La Roche 32
3.1.7 Gilotrif (afatinib) – Boehringer Ingelheim 34
3.2 Comparative Efficacy and Safety 34

4 Pipeline Products 37
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 39
4.3 Pipeline Analysis by Mechanism of Action 41
4.4 Clinical Trials 44
4.4.1 Failure Rate 44
4.4.2 Patient Enrollment and Clinical Trial Size 46
4.4.3 Duration 48
4.5 Promising Drug Candidates in the Pipeline 50
4.5.1 Ramucirumab (IMC-1121B) – Eli Lilly and Company 50
4.5.2 Necitumumab (IMC-11F8) – Eli Lilly and Company 50
4.5.3 Onartuzumab (MetMab) – F. Hoffmann-La Roche 51
4.5.4 Ganetespib (STA-9090) – Synta 52
4.5.5 Nintedanib (BIBF1120) – Boehringer Ingelheim 52
4.5.6 Dacomitinib (PF-00299804) – Pfizer 53
4.5.7 LDK378 – Novartis 54
4.5.8 Yervoy (ipilimumab) – Bristol-Myers Squibb 54
4.5.9 Nivolumab (BMS-936558/ONO-4538) – Bristol Myers Squibb 55

5 Market Forecast to 2019 56
5.1 Geographical Markets 56
5.1.1 APAC Market 56
5.1.2 India 57
5.1.3 Australia 60
5.1.4 China 62
5.1.5 Japan 64
5.2 Drivers and Barriers for the Disease Market 66
5.2.1 Drivers 66
5.2.2 Barriers 66

6 Deals and Strategic Consolidations 68
6.1 Major Co-development Deals 69
6.1.1 OxOnc Enters Co-development Agreement with Pfizer for Crizotinib 70
6.1.2 SFJ Pharma Enters Co-development Agreement with Pfizer for Dacomitinib 70
6.1.3 Merck Enters Co-development Agreement with Endocyte for Cancer Drug 71
6.1.4 Roche Enters Co-development Agreement with Clovis 71
6.1.5 Abbott Laboratories Enters Co-development Agreement with GlaxoSmithKline 71
6.2 Major Licensing Deals 71
6.2.1 Chugai Enters Licensing Agreement with Roche for Onartuzumab and Lebrikizumab 72
6.2.2 Azaya Enters Licensing Agreement with CANbridge Life Sciences for ATI-1123 73
6.2.3 Merck Expands Licensing Agreement with Biomira 73
6.2.4 Clovis Enters Licensing Agreement with Avila Therapeutics 73

7 Appendix 74
7.1 All Pipeline Drugs by Phase 74
7.1.1 Discovery 74
7.1.2 Preclinical 75
7.1.3 IND-filed 78
7.1.4 Phase I 78
7.1.5 Phase II 82
7.1.6 Phase III 86
7.1.7 Undisclosed 89
7.2 Market Forecasts to 2019 97
7.2.1 APAC 97
7.2.2 India 98
7.2.3 Australia 98
7.2.4 China 98
7.2.5 Japan 99
7.3 Market Definitions 99
7.4 Abbreviations 99
7.5 Bibliography 102
7.6 Research Methodology 105
7.6.1 Coverage 105
7.6.2 Secondary Research 106
7.6.3 Primary Research 106
7.6.4 Therapeutic Landscape 106
7.6.5 Geographical Landscape 108
7.6.6 Pipeline Analysis 109
7.7 Expert Panel Validation 109
7.8 Contact Us 109
7.9 Disclaimer 109

List of Tables

Table 1: Non-Small Cell Lung Cancer Market, Common Symptoms of Non-Small Cell Lung Cancer 11
Table 2: Non-Small Cell Lung Cancer Market, Risk Factors of Non-Small Cell Lung Cancer Market 12
Table 3: Non-Small Cell Lung Cancer Market, American Joint Committee on Cancer’s Tumor Node Metastasis Staging System, 2010 17
Table 4: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Discovery), 2013 74
Table 5: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 75
Table 6: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (IND-filed), 2013 78
Table 7: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase I), 2013 78
Table 8: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase II), 2013 82
Table 9: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase III), 2013 86
Table 10: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013 89
Table 11: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Forecast, 2012–2019 97
Table 12: Non-Small Cell Lung Cancer Market, India, Market Forecast, 2012–2019 98
Table 13: Non-Small Cell Lung Cancer Market, Australia, Market Forecast, 2012–2019 98
Table 14: Non-Small Cell Lung Cancer Market, China, Market Forecast, 2012–2019 98
Table 15: Non-Small Cell Lung Cancer Market, Japan, Market Forecast, 2012–2019 99

List of Figures

Figure 1: Non-Small Cell Lung Cancer Market, Asia-Pacific, Distribution of Prevalence Population, 2012–2019 16
Figure 2: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 20
Figure 3: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 21
Figure 4: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Advanced Metastatic Tumors, 2013 22
Figure 5: Non-Small Cell Lung Cancer Market, Global, Annual Sales, 2012 24
Figure 6: Non-Small Cell Lung Cancer Market, Global, Alimta (pemetrexed disodium) Annual Sales ($bn), 2004–2012 25
Figure 7: Non-Small Cell Lung Cancer Market, Global, Abraxane (nab-paclitaxel) Annual Sales ($m), 2009–2012 27
Figure 8: Non-Small Cell Lung Cancer Market, Global, Iressa (gefitinib) Annual Sales ($m), 2005–2012 28
Figure 9: Non-Small Cell Lung Cancer Market, Global, Tarceva (erlotinib) Annual Sales ($bn), 2006–2012 30
Figure 10: Non-Small Cell Lung Cancer Market, Global, Xalkori (crizotinib) Annual Sales ($m), 2012–2013 31
Figure 11: Non-Small Cell Lung Cancer Market, Global, Avastin (bevacizumab) Annual Sales ($bn), 2006–2012 33
Figure 12: Non-Small Cell Lung Cancer Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 35
Figure 13: Non-Small Cell Lung Cancer Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2013 38
Figure 14: Non-Small Cell Lung Cancer Market, Global, Pipeline by Molecule Type and Stage of Development, 2013 40
Figure 15: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, 2013 42
Figure 16: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2013 43
Figure 17: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Failure Rate (%), 2013 45
Figure 18: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Size (Participants), 2013 47
Figure 19: Non-Small Cell Lung Cancer Market, Global, Pipeline Clinical Trial Duration (months), 2013 49
Figure 20: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Size, 2012–2019 57
Figure 21: Non-Small Cell Lung Cancer Market, India, Market Size, 2012–2019 59
Figure 22: Non-Small Cell Lung Cancer Market, Australia, Market Size, 2012–2019 61
Figure 23: Non-Small Cell Lung Cancer Market, China, Market Size, 2012–2019 63
Figure 24: Non-Small Cell Lung Cancer Market, Japan, Market Size, 2012–2019 65
Figure 25: Non-Small Cell Lung Cancer Market, Global Deals by Value, Year and Stage of Development, 2006–2013 68
Figure 26: Non-Small Cell Lung Cancer Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006–2013 69
Figure 27: Non-Small Cell Lung Cancer Market, Global, Co-development Deals by Geography, 2006–2013 70
Figure 28: Non-Small Cell Lung Cancer Market, Global, Licensing Deals by Geography, 2006–2013 72
Figure 29: GBI Research Market Forecasting Model (Example) 108

Upcoming Reports:

Greece: market of plastic shutters and blinds
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the plastic shutters and blinds market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the plastic shutters and blinds market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Clean Coal Technology Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth and Forecast 2014 - 2020
By - Transparency Market Research
Coal is the major fuel for power generation and the thermal industry is expected to grow rapidly in the future. Rapid rise in demand for power around the world coupled with increasing urbanization, industrialization and a growing population is anticipated to boost the demand for power. Coal-fired thermal power plants account for the highest share in the global power-generation mix and it is most likely to dominate over the forecast period. However, conventional coal fired thermal power plant emits variety of harmful gases that pollute the atmosphere. Clean coal technologies are...
Opium Tincture Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
A tincture is an alcoholic extract of plant or animal material or solution of such low volatility substance. Tincture of opium which is also known as laudanum is an alcoholic herbal preparation containing approximately 10% powdered opium by weight. Opium is a highly narcotic drug acquired as dried latex that contains approximately 12% of the analgesic alkaloid morphine. It is obtained from opium poppy seeds (papaver somniferum). Opium is processed chemically to produce heroin and other synthetic opioids for medicinal use and other uses. Opium tincture is reddish brown in color and...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Under Armour Makes US$475 Million Deal for MyFitnessPal
Feb 26, 2015  
Baltimore based Under Armour has made earnest attempts in becoming one of the largest players in the fitness apparel market. In their latest venture, the company bought out MyFitnessPal for US$475 million on February 4, 2015. The company also purchased a smaller running app Endomondo for US$85 million. MyFitnessPal is a free fitness app that allows a user to keep a track of his/her...
Hanesbrands Buys Out Knights Apparel
Feb 26, 2015  
Hanesbrands Inc., a leading apparel retailer, has signed an agreement that will allow it to take over Knights Apparel for US$200 million in cash. The latter is a collegiate logo apparel seller. Analysts believe that the acquisition is a strategic one that will provide the right fit to the parent company. White Knights Apparel sells sweatshirts, T-shirts, and other sports apparel with...
Smartphone Market in India on Decline while Samsung Holds Top Spot
Feb 26, 2015  
Korean consumer electronics giant Samsung maintained its leadership in the India smartphone market. The company recorded a 22 per cent share in Q4 of 2014. The overall market has however, shrunk for the first time in history. Most manufacturers of smartphones have had a pileup of inventories in the October to December period, as said by IDC, a market research firm. The firm said that...
Apple to Face over $500 million Payout on iTunes Patent
Feb 26, 2015  
Recently, Apple was accused of using inventions knowingly which were owned by another business in iTunes. The tech giant suffered a patent loss which involved some of these technologies that were used by the iTunes store. As a result the company has been ordered to pay a fine of US$533 million to the company Smartfish. Smartfish is a company which is based in British Virgin Islands and...
Record Connection Speed Achieved by 5G Researchers
Feb 26, 2015  
A record breaking speed has been managed during the test of 5G data connection, according to scientists. The scientists at the University of Surrey’s for 5G Innovation Center or 5GIC were able to achieve a connection speed of 1 tera bit per second, which is thousands of times faster than current data connections. The head of the center at 5GIC stated that he hoped to...